Question - Does anyone use topical anesthesia (creams) for procedures? If so, what formulation do you use?

Question - Does anyone use topical anesthesia (creams) for procedures? If so, what formulation do you use?

Hi everyone, I'm happy to join you here. hope to find interesting topics to talk about and share interesting information.

Please right profile show me. 

Novo Nordisk said on Tuesday it would cut U.S. list prices for several insulin drugs by up to 75% next year, joining rival Eli Lilly as drugmakers come under pressure for high prices of the life-sustaining treatment.
The moves follow President Joe Biden's Inflation Reduction Act last year that capped insulin prices for Medicare recipients at $35 per month, but that does not extend to patients without insurance.
Novo will reduce the list price of its NovoLog insulin by 75%, and for Novolin and Levemir by 65%. The Danish drugmaker said the financial impact of the move was uncertain.
The company also said it would reduce the list price of unbranded insulin products to match lowered price of respective branded insulin products.
Eli Lilly and Co said earlier this month that it would cut the list prices for its most commonly prescribed insulin products by 70% from the fourth quarter of this year.
"I think it is a relatively natural consequence of what we have seen their competitor Eli Lilly do. We know there has been political pressure on this issue in general, it is a focus area in the U.S., especially for uninsured patients," Jyske Markets analyst Henrik Hallengreen Laustsen told Reuters.
Read more: https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-cut-price-insulin-by-up-75-wsj-2023-03-14/

Candidate AP30663 is an inhibitor for the conversion of atrial fibrillation to a normal sinus rhythm
Acesion Pharma – a company focused on novel therapies for atrial fibrillation (AF) – has announced positive results from a phase 2 trial of its candidate, AP30663. The therapy is a first-in-class SK ion channel inhibitor for the conversion of AF to a normal sinus rhythm.
The trial was placebo-controlled, randomised, double-blind and multi-national. The study enrolled 63 patients with a current episode of AF – the most common cardiac arrhythmia – and examined the performance of two intravenous doses of AP30663 compared to the placebo.
Meanwhile, the primary endpoint was the proportion of patients with AF conversion to sinus rhythm within 90 minutes of infusion commencing.
In addition, the research employed a ‘Bayesian analysis’ involving a probability less than 99.9% of a true AF conversion rate greater than the placebo across the two doses. The results from the Bayesian analysis were supported by a traditional analysis of the primary endpoint, demonstrating significant P-values for each dose compared to the placebo.
The safety profile was also consistent with that observed in previous phase 1 trials with AP30663, while the therapy was well tolerated, with no serious adverse events reported among the groups. The main safety concern with available AF treatments – ventricular arrhythmias – were not apparent throughout the trials.
John Camm, emeritus professor of clinical cardiology at St George’s University of London, reflected: “There is a great unmet need for safer AF treatments that can decrease the risk for patients, but also remove barriers for physicians wanting to keep their patients in sinus rhythm by treating them with an antiarrhythmic drug. This novel mechanism holds the promise to deliver on these aspects.”
Read more: https://www.pharmatimes.com/news/acesion_announces_positive_atrial_fibrillation_study_1489340

Neoteric Breakthrough in Scientific and Clinical Paradigms of Genomics and Proteomics
The Human Genome Project has changed biology and biological discoveries, paving the door for us to return to ambitious scientific cooperation.
As a result, the principles of genomics and proteomics have established themselves as essential tools for novel diagnostic approaches and medical research. Rapid advancements in high throughput technology for genetic and proteomic profiling have contributed to the much-anticipated development of tailored treatment for complicated disorders. Want to learn such interesting facts about human genome? Why wait - Join us at our Next-Gen Genomics and Proteomics Conference, organized by MarketsandMarkets, in London, UK, on March 9th and 10th, 2023.
The conference will incorporate a variety of sessions, including those on functional genomics and organellar proteomics in biomedicine, applied and translational genomics, epigenomics in systems biology, immune phenotyping using Flowcytometry and Immuno Metabolic Markers-Polygenic Risk Scores, next-generation sequencing and single-cell sequencing for disease diagnosis, electrospray mass spectrometry-based biomarkers, multidimensional liquid chromatography in clinical proteomics, and genome-wide variations. The gathering includes networking opportunities, panel talks, and services geared towards genomics and proteomics research. To give a broad view of cutting-edge research and development in the field of multi-Omics research, the conference will bring together a wide range of experts, leaders, and stakeholders.
Conference Registration: https://events.marketsandmarkets.com/genomics-and-proteomics-conference/register

Consider following MEDAMETHEUS on LinkedIn, especially if you need a versatile medical affairs partner!

http://www.4catalyzer.com, founded by Jonathan Rothberg, is hiring a Molecular Biologist for their newest genomics start-up company, 454 Bio.
This is an exciting GROUND FLOOR opportunity!
454 is a group of leading genomics experts who are developing a DNA sequencing platform for use at home, for under $100 – it’s an innovative product and an exciting time to join the team!
You would play a critical role & work with the company’s founders to develop next-gen molecular biology systems to interface with novel engineering platforms.
We're looking for someone with experience in:
- library preparation and amplification on a solid support
- DNA patterned array design, development, and production
Here is the role: https://www.4catalyzer.com/careers?gh_jid=5326749003
Please get in touch for more information - happy to provide full details.
The lab is based in Guilford, CT.
Visa sponsorship can be considered.

Quality risk management is a crucial element for addressing risks as applied to analytical procedures, especially in the pharmaceutical industry. Failing to address quality risks in the design, development, and manufacture of drug substances and products has potent implications including market withdrawal, recall, rejections, and endangering patient safety.
Through this article understand the importance of Integrating a Risk-Based Approach for Informed Decision-Making for Pharmaceutical Products.

Hello! I am thrilled to be here!!! I look forward to learning so much from everyone. Thanks for having me!

Ipsen has revealed follow-up results from its phase 3 CheckMate-9ER trial. The study demonstrated that Cabometyx in combination with nivolumab provides survival benefits after three-years of treating advanced renal cell carcinoma (RCC), compared to sunitinib.
During the CheckMate -9ER trial, overall survival benefits were maintained during three-years of follow-up. Meanwhile, median overall survival was significantly higher for patients on Cabometyx (also known as cabozantinib) together with nivolumab versus sunitinib.
Accounting for around 90% of cases, RCC is the most common type of kidney cancer. When detected at an early stage, the five-year survival rate is high, but for people living with advanced or late-stage metastatic RCC the survival rate is considerably lower – around 12%.
The study results were also assessed by the following International Metastatic Renal Cell Carcinoma Database Consortium risk scores. Benefits were duly identified with Cabometyx in combination with nivolumab across all efficacy measures, regardless of IMDC risk.
Steven Hildemann, executive vice president at Ipsen, explained: “The results from the CheckMate -9ER study continue to demonstrate sustained, now three-year long-term benefits for people living with advanced renal cell carcinoma across the most meaningful efficacy measures and risk scores, adding to the body of evidence we have for Cabometyx plus nivolumab.
Read more: https://www.pharmatimes.com/news/positive_results_for_ipsens_cabometyx_in_combination_with_nivolumab_1486624

Our manufacturing team is proudly bridging a gap in supply of consumables to governments, laboratories, hospitals and research facilities, globally.We value our customers needs and provide quality products, friendly service and timely deliveries.We are seeing the demand for an alternative supplier, and we are the solution for the future.Looking forward to connecting, and happy to help.

Good morning All! I am new to PharmeMed. Very excited to be here, to learn, and hopefully get to know some of you. 

Phase 3 study demonstrated that efanesoctocog alfa met both primary and secondary endpoints
Research has demonstrated positive safety, efficacy and pharmacokinetic credentials of Sanofi’s efanesoctocog alfa drug.
The therapy is an investigational treatment for haemophilia A and the data showed that it delivered a normal to near-normal factor activity levels for the most of the week during a once-a-week dosing pattern.
Haemophilia A is a lifelong, rare and genetic condition affecting the ability of a person’s blood to clot, and occurs in about one in 5,000 male births every year, while being uncommon in females. Individuals can experience bleeding episodes that can cause irreversible joint damage, severe pain and life-threatening haemorrhages.
Data from the vital XTEND-1 phase 3 study demonstrated that efanesoctocog alfa – also known as ALTUVIIIO – met both primary and secondary endpoints, showing clinically meaningful prevention of bleeds and superior bleed protection compared to prior factor VIII prophylaxis treatment.
Dietmar Berger, global head of development and chief medical officer at Sanofi, reflected: “We are steadfast in our commitment to developing novel treatment options that have a meaningful impact for patients.”
He added: “We are hopeful that efanesoctocog alfa will help deliver on this goal by offering unprecedented factor activity levels with once-weekly dosing, fulfilling its potential as a best-in-class therapy for haemophilia A.”
Read more: https://www.pharmatimes.com/news/sanofis_efanesoctocog_alfa_may_be_game-changer_for_haemophilia_a_patients_1486092